S'abonner

Remission of persistent childhood asthma: Early predictors of adult outcomes - 04/05/19

Doi : 10.1016/j.jaci.2018.09.038 
Alberta L. Wang, MD a, b, Soma Datta, MS a, Scott T. Weiss, MD a, Kelan G. Tantisira, MD a, c,
a Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass 
b Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass 
c Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass 

Corresponding author: Kelan G. Tantisira, MD, Channing Division of Network Medicine, Brigham and Women's Hospital, 181 Longwood Ave, Boston, MA 02115.Channing Division of Network MedicineBrigham and Women's Hospital181 Longwood AveBostonMA02115

Abstract

Background

Few data exist on the predictors of asthma remission by early adulthood in North America.

Objective

The predictors of adult asthma remission were determined in a multiethnic population of patients with mild-to-moderate persistent childhood asthma.

Methods

Asthma remission in early adulthood was measured by using 2 definitions: a clinical and a strict definition. Both included normal lung function and the absence of symptoms, exacerbations, and medication use. The strict definition also included normal airways responsiveness. Predictors were identified from 23 baseline measures by using multivariate logistic regression. The probability of remission was modeled by using decision tree analysis.

Results

In 879 subjects the mean ± SD baseline age was 8.8 ± 2.1 years, 59.4% were male, and 68.7% were white. By adulthood, 229 (26.0%) of 879 participants were in clinical remission, and 111 (15.0%) of 741 participants were in strict remission. The degree of FEV1/forced vital capacity (FVC) ratio impairment was the largest predictor of asthma remission. More than half of boys and two thirds of girls with baseline FEV1/FVC ratios of 90% or greater were in remission at adulthood. Decreased airways responsiveness was also a predictor for both remission definitions (clinical remission odds ratio, 1.23 [95% CI, 1.09-1.39]; strict remission odds ratio, 1.52 [95% CI, 1.26-1.84]). The combination of normal FEV1/FVC ratio, airways responsiveness, and serum eosinophil count at baseline yielded greater than 80% probability of remission by adulthood.

Conclusion

A considerable minority of patients with persistent childhood asthma will have disease remission by adulthood. Clinical prognostic indicators of asthma remission, including baseline lung function, can be seen from an early age.

Le texte complet de cet article est disponible en PDF.

Graphical abstract




Le texte complet de cet article est disponible en PDF.

Key words : Pediatric asthma, asthma remission, prognostication

Abbreviations used : AUC, BHR, CAMP, FVC, OR


Plan


 Supported by National Institutes of Health (NIH) grants T32 AI007306, T32 HL007427, R01 HL127332, R01 HL129935, and U01 HL65899. The Childhood Asthma Management Program (CAMP) trial and CAMP Continuation Study were supported by contracts NO1-HR-16044, 16045, 16046, 16047, 16048, 16049, 16050, 16051, and 16052 with the National Heart, Lung, and Blood Institute and General Clinical Research Center grants M01RR00051, M01RR0099718-24, M01RR02719-14, and RR00036 from the National Center for Research Resources. The CAMP Continuation Study/Phases 2 and 3 were supported by grants U01HL075232, U01HL075407, U01HL075408, U01HL075409, U01HL075415, U01HL075416, U01HL075417, U01HL075419, and U01HL075420 from the National Heart, Lung, and Blood Institute. The National Jewish Health site was also supported in part by Colorado CTSA grant UL1RR025780 from the National Center for Research Resources/NIH and UL1TR000154 from National Center for Advancing Translational Sciences/NIH.
 Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.


© 2018  Publié par Elsevier Masson SAS.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 143 - N° 5

P. 1752 - mai 2019 Retour au numéro
Article précédent Article précédent
  • Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma
  • Sumita Khatri, Wendy Moore, Peter G. Gibson, Richard Leigh, Arnaud Bourdin, Jorge Maspero, Manuel Barros, Roland Buhl, Peter Howarth, Frank C. Albers, Eric S. Bradford, Martyn Gilson, Robert G. Price, Steven W. Yancey, Hector Ortega
| Article suivant Article suivant
  • A computerized decision support tool to implement asthma guidelines for children and adolescents
  • Carolyn M. Kercsmar, Christine A. Sorkness, Agustin Calatroni, Peter J. Gergen, Gordon R. Bloomberg, Rebecca S. Gruchalla, Meyer Kattan, Andrew H. Liu, George T. O'Connor, Jacqueline A. Pongracic, Stanley J. Szefler, Stephen J. Teach, Jeremy J. Wildfire, Robert A. Wood, Edward M. Zoratti, William W. Busse, National Institute of Allergy and Infectious Diseases–sponsored Inner-City Asthma Consortium

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.